Changes to our trading names and address – MSD and Organon & Co. read more

Changes to our trading names and address

Please note that in 2021, MSD will be spinning off products from its women’s health, legacy brands, and biosimilars franchises into a new independent, publicly traded company known as Organon & Co.

Due to legal entity separation in advance of this spin off, we now have two UK registered businesses, MSD and Organon. Organon & Co. is a wholly owned subsidiary of Merck & Co., Inc. of Kenilworth, New Jersey, USA.

As a result of the future spin-off of Organon, as well as our head offices moving to London in early 2021, you will begin to see some changes to references to our products, contact details, materials and statements over the coming months.


Partnerships

 

MSD PARTNERSHIPS

MSD believes in the power of partnership. We recognise that no single organisation has everything it takes to deliver complete healthcare.

WE ARE A COMMITTED PARTNER TO THE NHS

Together we are transforming healthcare through scientific excellence and ground-breaking collaborations to help address the challenge of reducing cost and deliver real benefits to UK patients.

We work closely with UK bodies such as the NHS, NICE and MHRA to ensure new medicines are brought to patients as quickly as possible. This has included working with stakeholders on providing medicines through Early Access to Medicines Scheme and the Cancer Drugs Fund. We also invest in research partnerships with the NHS and UK academic centres.

 
 

OUR WORK TRANSCENDS THE TRADITIONAL DEFINITION OF HEALTHCARE

Technology is revolutionising how we manage healthcare and MSD is at the heart of it.

Our people know medicines alone can't guarantee good health, so we are constantly innovating beyond the pill to develop new models of patient care and approaches to population health.

 

NHS JOINT WORKING

We have a long history of working in partnership with others. Indeed, some of our greatest achievements have come about through collaborative effort.

The Department of Health (DH) defines joint working between the NHS and the pharmaceutical industry as situations where, for the benefit of patients, one or more pharmaceutical companies and the NHS pool skills, experience and/or resources for the joint development and implementation of patient-centred projects and share a commitment to successful delivery. Our ability to continue with our long-standing collaborative efforts pivots on the DH’s joint working mandate and enables us to discover and invent new ways, every day, to help patients, their families and their loved ones.

We're currently working with the NHS in numerous ways, across various disciplines and disease areas. Whether it's cost reductions, improved quality of patient care or access to the latest research in a specialist area, we do what we can to help.

OUR JOINT WORKING PARTNERSHIPS

2020

2019

2018

2017

Manchester University NHS Foundation Trust Patient Experience App
EPIC: Early Prehabilitation In Lung Cancer
Cardiff and Vale University Health Board Diabetes Informatics Programme
SIMP-L
Hepatitis C (HCV) testing within existing Tuberculosis (TB) testing service for patients (local and immigrants) in Newham, London.
Over 65s Vaccination GP Cluster Project
Greater Manchester optimal lung cancer pathway project
Diabetes Informatics Project – NHS Warrington CCG
Northern Cancer Alliance Lung Pathway Board Project
London Joint Working Group (LJWG) for Substance Use and Hepatitis C & MSD: Phase 2 - RNA Hepatitis C Testing in Community Pharmacy
SAS‐HYPO‐FIFE
Over 65 Vaccine Project Northern Ireland
NHS Buckinghamshire Diabetes Change Management Programme
East Merton GP surgeries EiP with Wide Way Surgery, Tamworth House Medical Centre, Cricket Green Medical Practice, Figges Marsh Surgery, Ravensbury Park Medical Centre, The Rowens Surgery and Streatham Commons Group Practice
Wessex AHSN Diabetes STP
Derbyshire pharmacy testing initiative for hepatitis C and HIV
Evidence Into Practice Across General Practices in Cardiff South West Cluster
Redbridge EiP Cluster (3)
Evidence Into Practice across Warrington CCG
Wessex Skin Mapping Project
Increasing the detection and diagnosis of blood borne viruses within the General Practice Population in BCUHB
Reducing Unwanted Pregnancies Programme within Drug and Alcohol Services in Wales
Merton GP surgeries Primary Care Change Programme for Diabetes with Colliers Wood surgery, Mitcham Family Practice and Mitcham Medical Centre
 

HEALTHCARE TECHNOLOGY

The use of innovative technology is a key priority for the NHS and is revolutionising the management of healthcare to improve healthcare outcomes.

Here at MSD, we have a rich legacy of invention, learnings and insights through providing innovative healthcare solutions that we can bring to support partnership projects to improve patient care now and, in the future, and will continue to drive this forward through:

Exploring and developing partnerships to deliver innovative healthcare solutions to help address health challenges now and in the future.

Finding innovative technology organisations to partner to help improve patient experiences, treatment pathways and diagnoses.

Collaborating to create patient-focused solutions.

 

MSD is proud to have worked across a number of partnership projects in what has been an incredible journey to look at innovative ways of providing healthcare and testing out new ideas and approaches for the first time.

From conducting long term condition algorithm development with Verily as part of the first wave of NHSE’s flagship Test Bed Programme, to partnering with pharmacies to deliver patient support programmes that improve compliance to medications, we are always learning.

We have also been involved in an early Detection of Cancer capability in support of the Cancer Vanguard and played a part in population health management at scale, as the technology partner for National Services Scotland, where we supported the application of data and digital to develop services across multiple domains of care through the SPIRE programme.

Our learnings and insights have been instrumental in helping us to spearhead and shape current partnership projects across diverse areas of innovative healthcare.

OUR AMBITION

To continue to use our rich legacy of invention, learnings and insights to help improve patient care by exploring and developing new models of working with innovative partners to deliver healthcare solutions to help address health challenges now and in the future.

 

PARTNERING WITH THIRD PARTY ORGANISATIONS

PATIENT ORGANISATIONS

We have a long history of working with patient organisations to enable people to make informed choices about their health. It's one of the most important things we do – and we're proud of it.

Our aim is to support access to useful, accurate information to improve health and advance patient care.

 

For details of our past and present activities, please click on the links below:

Patient Organisations

Other Third-Party Organisations

 

HEALTHCARE PROFESSIONALS

Payments to Health Professionals and Healthcare Organisations.

MSD is passionate about advancing health and providing life-saving medicines to patients through innovation but we cannot do this without the vital scientific knowledge and insight health professionals (HCPs) bring, or close collaboration with healthcare organisations (HCOs).

The pharmaceutical industry is committed to greater transparency of financial relationships with HCPs and HCOs.

As a member of the Association of the British Pharmaceutical Industry (ABPI), MSD supports this and has already been disclosing anonymised aggregate payments and benefits to HCPs and HCOs for the last three years in the lead up to individual disclosure.

ABPI logo

TRANSPARENCY

We're bold enough to want to change the world, but we're smart enough to know we can't do it alone.

In our quest to discover and develop innovative medicines, we are proud to work with many experts to bring medicines from the molecule to the patient care-setting.

We aspire to be open and transparent about these collaborations. We know we must continue to deserve the trust and confidence of patients, and also our customers, employees, shareholders and anyone else who connects with our business.

Our industry is actively involved in developing and adopting practices which help share information appropriately and with increasing transparency. This is an evolutionary process which is happening both in the UK and around the world. (ABPI)(IFPMA).

INDIVIDUAL DISCLOSURE

MSD, along with other ABPI member companies, discloses details of certain Transfer of Value (ToV) payments and benefits to individually named HCPs and HCOs on a publicly searchable database, Disclosure UK, which is hosted on the ABPI website.

For details of MSD’s individual payments to HCPs and HCOs

CLICK HERE

Click here for our methodology report.

 

GRANTS

We have a long history of working with and supporting patient organisations to enable people to make informed choices about their health. It’s one of the most important things we do – and we’re proud of it.

This year, we launched two Grants Programmes; a COVID-19 UK Dedicated Grants Programme and an MSD Therapy Area Community Grants Programme. Applications for these Grants are now closed.

We have received unprecedented interest in these programmes and are grateful to all organisations for their time and effort in applying. We are in the process of reviewing all applications and are aiming to communicate grant awards from September onwards.

Please contact grantscommittee@msd.com if you have any questions regarding your application. Details of 2021 MSD Grants Programmes will be available in due course.

MSD FOR MOTHERS

NEIGHBOUR OF CHOICE

GLOBAL ONCOLOGY

MSD FOR MOTHERS

MSD for Mothers For over a century, MSD has taken on the most urgent global health challenges, including diabetes, HIV/AIDS and cervical cancer. Maternal mortality is no exception. MSD for Mothers builds on this legacy by implementing programmes, partnerships and solutions so no woman dies giving life.

Find out more here

NEIGHBOUR OF CHOICE

Our Neighbour of Choice (NOC) community grant programme supports the work of local non-profit organisations that strive to improve people’s quality of life and to preserve the environment in communities in which we have a presence. Established by MSD globally in the 1990s, the NOC programme fosters partnerships with local non-profit organisations whose mission is to promote the well-being of community residents. We provide financial resources, enhanced by employee volunteerism, to support community programmes that aim to improve healthcare quality and protect the environmental health of the local community.

GLOBAL ONCOLOGY

Cancer represents one of the world’s most urgent unmet medical needs. Worldwide, more than 14 million new cancer cases were diagnosed in 2012. This number is expected to grow to more than 20 million by 2030. We believe that policy researchers play a critical role – through their research work, educational activity and public outreach in informing valuable policy dialogues through evidence. Through this Independent Oncology Policy Grant Programme, MSD aims to enable institutions to enhance their capacity in research, teaching and dissemination. Beyond supporting independent research, the Programme will provide a forum for researchers to share ideas on emerging cancer policy issues and identify new areas for policy study.

Find out more about our Global Oncology Grants here

To find out more about MSD’s Corporate Social Responsibility

CLICK HERE

Job code: GB-NON-03104

Date of preparation: August 2020

 

  • PARTNERSHIPS